This means that passive immunization with tau antibodies is usually a viable therapeutic target and which the CSF amount of p-tau262/356 or with the microtubule binding domain (MTBD) can serve as a useful biomarker of tau pathology to watch tau therapeutics in scientific trials.In the La Biennale di Venezia Web-site: “Her fantastical bodies impro